Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents

10 Dec 2016

Abstract excerpt

Quiescent proviral genomes that persist during human immunodeficiency virus type 1 (HIV-1) infection despite effective antiretroviral therapy (ART) can fuel rebound viremia after ART interruption and is a central obstacle to the cure of HIV infection. The induction of quiescent provirus is the goal of a new class of potential therapeutics, latency reversing agents (LRAs). The discovery, development, and testing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28520964
DOI: 10.1093/infdis/jiw618

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing AgentsPMID 28520964Read ↗

The role of latency reversal in HIV cure strategiesSemantic proximity Read ↗

Curing HIV: Pharmacologic Approaches to Target HIV-1 LatencySemantic proximity Read ↗

HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency StudiesSemantic proximity Read ↗

Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a CureSemantic proximity Read ↗

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue ReservoirsSemantic proximity Read ↗

Cellular and molecular mechanisms involved in the establishment of HIV-1 latencySemantic proximity Read ↗

Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent VorinostatSemantic proximity Read ↗

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV CureSemantic proximity Read ↗

The Current Status of Latency Reversing Agents for HIV-1 RemissionSemantic proximity Read ↗

HIV-1 Latency and Latency Reversal: Does Subtype Matter?Semantic proximity Read ↗

Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirsSemantic proximity Read ↗

The multifaceted nature of HIV latencySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.